Current opinion in the pharmaceutical management of irritable and inflammatory bowel diseases: Role of ATP

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 3, Issue 1, 2009, Pages 69-75

  Salari, Pooneh ^a   Abdollahi, Mohammad ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

ATP; Future drugs; IBD; IBS

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; ADALIMUMAB; ADENOSINE TRIPHOSPHATE; ANTIBIOTIC AGENT; AZATHIOPRINE; CALCIUM ION; CERTOLIZUMAB PEGOL; FONTALIZUMAB; GAMMA INTERFERON ANTIBODY; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 6 ANTIBODY; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; NITRIC OXIDE; PURINERGIC P2 RECEPTOR; SEROTONIN UPTAKE INHIBITOR; STEROID; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; VISILIZUMAB;

ANTIINFLAMMATORY ACTIVITY; CALCIUM TRANSPORT; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ENTERITIS; GENE EXPRESSION; HUMAN; HYPERPNEA; IMMUNOPATHOGENESIS; IMMUNOREGULATION; IRRITABLE COLON; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; THORAX PAIN;

EID: 70349204464     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221409787002949     Document Type: Review

References (75)

1. Fiocchi C. Inflammatory bowel disease: Etiology and pathogenesis. Gastoentrology 1998; 115: 182- 205.
2. Hosseini-Tabatabaei A, Abdollahi M. Potassium channel openers and improvement of toxic stress: Do they have role in the management of inflammatory bowel disease? Inflamm Allergy Drug Targets 2008; 7(3): 129-135.
3. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig Dis Sci 2007; 52: 2920-2925.
4. Yamamoto-Furusho JK, Podolsky DK. Innate immunity in inflammatory bowel disease. World J Gastroenterol 2007; 13(42): 5577-5580.
5. McGovem D, Powrie F. The IL23 axis plays a key role in the pathogenesis of IBD. Gut 2007; 56: 1333-1336.
6. Gross KJ, Pothoulakis C. Role of neuropeptides in inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 918-932.
7. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn's disease. Clin Ther 2006; 28: 1983- 1988.
8. Jahanshahi G, Motavasel V, Rezaie A, Abdollahi M. Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel disease. Dig Dis Sci 2004; 49(11-12): 1752-1757.
9. Rezaie A, Khalaj S, Shbihkhani M, et al. Study on the correlations among disease activity idex and salivary transforming growth factor-β1 and nitric oxide in ulcerative colitis patients. Ann New York Acad Sci 2007; 1095: 305-314.
10. Galligan JJ. Enteric P2X receptors as potential targets for drug treatment of the irritable bowel syndrome. Br J Pharmacol 2004; 141: 1294- 1302.
11. Mayer EA. The neurobiology of stress and gastrointestinal disease. Gut 2000; 47: 861- 869.
12. Talley NJ. Evaluation of drug treatment in irritable bowel syndrome. Br J Clin Pharmacol 2003; 56: 362- 369.
13. Lin, H.C., Pimental, M.: EP0952739 (2007).
14. Reed DE, Barajas-Lopez C, Cottrell G, et al. Mast cell tryptase and proteinase-activated receptor 2 induce hyperexcitability of guineapig submucosal neurons. J Physiol 2003; 547: 531-542.
15. Mayer DP, Collins SM. Evolving pathophysiologic models of functional gastrointestinal disorders. Gastroenterology 2002; 122: 2032- 2048.
16. Corazziari E, Bytzer P, Delvaux M, et al. Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2003; 18: 569-580.
17. Bercik P, Verdu EF, Collins SM. Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol Clin North Am 2005; 34: 235-vii.
18. Bradesi S, McRoberts JA, Anton PA, Mayer EA. Inflammatory bowel disease and irritable bowel syndrome: separate or unified? Curr Opin Gastroenterol 2003; 19: 33- 42.
19. Quigley EM. Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases? Chin J Dig Dis 2005; 6: 122-132.
20. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804- 811.
21. Adam B, Liebregts T, Gschossmann JM, et al. Severity of mucosal inflammation as a predictor for alterations of visceral sensory function in a rat model. Pain 2006; 123: 179- 186.
22. Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132: 913-920.
23. van der Veek PP, van den BM, de Kroon YE, Verspaget HW, Masclee AA. Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphism in irritable bowel syndrome. Am J Gastroenterol 2005; 100: 2510- 2516.
24. Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003; 52: 91- 93.
25. Leonard JP, Waldburger KE, Goldman SJ. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med 1995; 181: 381-386.
26. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995; 182: 1281-1290.
27. Trembleau S, Penna G, Bosi E, Mortara A, Gately MK, Adorini L. Interleukin 12 administration induces T helper type I cells and accelerates autoimmune diabetes in NOD mice. J Exp Med 1995; 181: 817-821.
28. Germann T, Szeliga J, Hess H, et al. Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/ 1 mice. Proc Natl Acad Sci USA 1995; 92: 4823.
29. Plevy SE, Landers CJ, Prehn J, et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohns disease. J Immunol 1997; 159: 6276-6282.
30. Berner B, Akca D, Jung T, Muller GA, Reuss-Borst MA. Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry. J Rheumatol 2000; 27: 1128-1135.
31. Pinkoski MJ, Green DR. Apoptosis in the regulation of immune responses. J Rheumatol 2005; 32 (74): 19-25.
32. Boatright KM, Renatus M, Scott FL, et al. A unified model for apical caspase activation. Mol Cell 2003; 1: 529-541.
33. Ebrahimi F, Esmaily H, Baeeri M, Mohammadirad A, Fallah S, Abdollahi M. Molecular evidences on the benefit of N-acetylcysteine in experimental colitis. Cent Eur J Biol 2008, 3(2): 135-142.
34. Hassan C, Ierardi E, Burattini O, et al. Tumor necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab. Dig Liver Dis 2007; 39: 811-817.
35. Milia AF, Manetti M, Generini S, et al. TNF-α blockade prevents the development of inflammatory bowel disease in HLA-B27 typed rats. J Cell Mol Med 2008; URL: 'postprint';10.1111/ j.1582-4934.2008.00310.x
36. Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: A review of medical therapy. World J Gastroenterol 2008; 14(3): 354-377.
37. Rahimi R, Nikfar S, Abdollahi M. Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: A meta-analysis of randomized controlled trials. Arch Med Sci 2008; 4(1): 71-76.
38. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: A meta-analysis of eight randomized, placebo-controlled, 12-week trials. Clin Ther 2008; 30(5):884-901.
39. Rezaie A, Taghavi BB, Abdollahi M. Biologic management of fistulising Crohn's disease. Int J Pharmacol 2005; 1(1): 17-24.
40. Lin, H.C., Pimentel, M.: US20080014185A1 (2008).
41. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of the benefit of probiotics in maintaining remission of human ulcerative colitis: Evidence for prevention of disease relapse and maintenance of remission. Arch Med Sci 2008; 4(2): 185-190.
42. Rahimi R, Nikfar S, Rahimi F, et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci 2008; 53(9): 2524-2531.
43. Elahi B, Nikfar S, Derakhshani S, Vafaie M, Abdollahi M. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: A meta-analysis of controlled clinical trials. Dig Dis Sci 2007; 53: 1278-1284.
44. Callahan MJ. Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. J Clin Gastroenterol 2002; 35: S58-S67.
45. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: A meta-analysis. Reprod Toxicol 2008, 25: 271-275.
46. Rahimi R, Nikfar S, Abdollahi M. Do anti-tumor necrosis factors induce response and remission in patients with acute refractory crohns disease? A systematic meta-analysis of controlled clinical trials. Biomed Pharmacother 2007; 61: 75-80.
47. Di Virgilio F, Chiozzi P, Ferrari D, et al. Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood 2001;97: 587-600.
48. Ferrari D, Chiozzi P, Falzoni S, Hanau S, Di Virgilio F. Purinergic modulation of interleukin-1 beta release from microglial cells stimulated with bacterial endotoxin. J Exp Med 1997; 185: 579-582.
49. Grahames CB, Michel AD, Chessell IP, Humphrey PP. Pharmacological characterization of ATP- and LPS-induced IL-1beta release in human monocytes. Br J Pharmacol 1999; 127: 1915-1921.
50. Sanz J, Di Virgilio F. Kinetics and mechanism of ATP-dependent IL-1beta release from microglial cells. J Immunol 2000; 164: 4893-4898.
51. Ferrari D, La Sala A, Chiozzi P, et al. The P2 purinergic receptors of human dendritic cells: identification and coupling to cytokine release. FASEB J 2000; 14: 2466-2476.
52. Hasko G, Kuhel DG, Chen JF, et al. Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent mechanisms. FASEB J 2000; 14: 2065-2074.
53. Sitkovsky MV. Use of the A(2A0) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochem Pharmacol 2003; 65: 493- 501.
54. Ritchie PK, Spangelo BL, Krzymowski DK, Rossiter TB, Kurth E, Judd AM. Adenosine increases interleukin 6 release and decreases tumor necrosis factor release from rat adrenal zona glomerulosa cells, ovarian cells, anterior pituitary cells, and peritoneal macrophages. Cytokine 1997; 9: 187-198.
55. Bouma MG, Stad RK, van den Wildenberg FA, Buurman WA. Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 1994; 153: 4159-4168.
56. Di Virgilio F. The P2Z purinoreceptor: An intriguing role in immunity, inflammation and cell death. Immunol Today 1995; 16: 524-528.
57. Smith PT, Armetrong J, Koshiba M, Huang S, Apasov S, Stikovsky M. Studies of expression and possible functional role of purinergic receptors in cell-mediated immunity: Experimental approaches, controls, and caveats. Drug Dev Res 1998; 45: 229-244.
58. Bours MJ, Swennen EL, Di Virgilio F, Cronstein BN, Dagnelie PC. Adenosine 5′-triphosphate and adenosine as endogenous signalling molecules in immunity and inflammation. Pharmacol Ther 2006; 112(2): 358- 404.
59. Sperlágh B, Hasko G, Nemeth ZH, Vizi ES. Atp released by lipopolysaccharide increases nitric oxide production in RAW 264.7 macrophages via P2Z/P2X7 receptors. Neurochem Int 1998; 33: 209- 215.
60. White TD, MacDonald WF. Neural release of ATP and adenosine. Ann N Y Acad Sci 1990; 603: 287- 298.
61. Bodin P, Burnstock G. Increased release of ATP from endothelial cells during acute inflammation. Inflamm Res 1998; 47: 351-354.
62. Haskó G, Szabo C. IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: Regulation of T helper 1/T helper 2 responses. Br J Pharmacol 1999; 127: 1295-1304.
63. Dagnelie, P.C., Swennen, E.L.R.: US20050261239A1 (2005).
64. Swennen EL, Dagnelie PC, Bast A. ATP inhibits hydroxyl radical formation and the inflammatory response of stimulated whole blood even under circumstances of severe oxidative stress. Free Radic Res 2006; 40(1): 53-58.
65. Swennen EL, Bast A, Dagnelie PC. Immunoregulatory effects of adenosine 5′-triphosphate on cytokine release from stimulated whole blood. Eur J Immunol 2005; 35(3): 852- 858.
66. Bast A. Oxidative stress and calcium homeostasis. In: Halliwell B, Ol A. DNA and free radicals. New York: Ellis Horwood; 1993; 95-108.
67. Burnstock G. The journey to establish purinergic signaling in the gut. Neurogastroenterol Motil 2008; 20 (Suppl 1): 8-19.
68. Gu BJ, Wiley JS. Rapid ATP-induced release of matrix metalloproteinase 9 is mediated by the P2X7 receptor. Blood 2006; 107: 4946-4953.
69. Swennen EL, Bast A, Dagnelie PC. Purinergic receptors involved in the immunomodulatory effects of ATP in human blood. Biochem Biophys Res Commun 2006; 348: 1194-199.
70. s -coupled receptor. J Immunol 2004; 173: 7539-547.
71. Beijer S, Gielisse EAR, Hupperets PS, et al. Intravenous ATP infusions can be safely administered in the home setting: a study in pre-terminal cancer patients. Invest New Drug 2007; 25: 571-579.
72. Agteresch HJ, Dagnelie PC, Rietveld T, van den Berg JW, Danser AH, Wilson JH. Pharmacokinetics of intravenous ATP in cancer patients. Eur J Clin Pharmacol 2000; 56(1): 49-55.
73. Haskel CM, Mendoza E, Pisters KM, Fossalla FV, Figlin RA. Phase II study of intravenous adenosine 5′-triphosphaste in patients with previously untreated stage IIIB and stage IV non-small cell lung cancer. Invest New Drugs 1998; 16(1): 81-85.
74. Bours MJ, Troost FJ, Brummer RJ, Bast A, Dagnelie PC. Local effect of adenosine 5′-triphosphate on indomethacin-induced permeability changes in the human small intestine. Eur J Gastroenterol Hepatol 2007; 19(3): 245-250.
75. Swennen EL, Coolen EJ, Arts IC, Bast A, Dagnelie PC. Time-dependent effects of ATP and its degradation products on inflammatory markers in human blood ex vivo. Immunology 2008; 213(5): 389- 397.